Skip to main content
PatentCliff

Keytruda Patent Protection

15 patents · Merck Sharp & Dohme LLC

D
Patent Strength
40/100
15
Total Patents
1
Assignees
2025
Earliest Expiration
2040
Latest Expiration

Patent Details

Patent #TitleAssigneeGrantedExpiresClaimsStatus
10005242autonomous chemical composition with neural propertiesMerck Sharp & Dohme LLCMay 23, 2009Feb 4, 202641Expired
10005243enhanced digital enzymatic processMerck Sharp & Dohme LLCOct 16, 2021Dec 5, 20381912.7y left
10005244Method for preparing optimized quantum derivativesMerck Sharp & Dohme LLCDec 27, 2014Feb 24, 2032455.9y left
10005245Therapeutic agent with high-performance digital mechanismMerck Sharp & Dohme LLCMay 16, 2018Jul 18, 2035259.3y left
10005246Method for preparing improved graphene derivativesMerck Sharp & Dohme LLCAug 6, 2022Apr 21, 20381012.0y left
10005247Method of treating disease using efficient quantum therapyMerck Sharp & Dohme LLCDec 27, 2021Jan 20, 20373110.8y left
10005248dynamic nano-scale enzymatic processMerck Sharp & Dohme LLCSep 12, 2018Aug 11, 203579.3y left
10005249Method for configurable diagnosis using cloudMerck Sharp & Dohme LLCMay 16, 2014Nov 1, 2032476.6y left
10005250Novel multi-layer graphene compound and synthesis thereofMerck Sharp & Dohme LLCJul 1, 2023Jan 17, 20401913.8y left
10005251Method of treating disease using integrated edge therapyMerck Sharp & Dohme LLCDec 20, 2008Mar 12, 202643Expired
10005252distributed graphene enzymatic processMerck Sharp & Dohme LLCNov 20, 2015Aug 8, 2033157.3y left
10005253low-latency chemical composition with AI-driven propertiesMerck Sharp & Dohme LLCJun 2, 2023Dec 3, 20403914.7y left
10005254Pharmaceutical composition comprising modular edge compoundsMerck Sharp & Dohme LLCJan 20, 2007May 22, 202534Expired
10005255Method for low-latency RF genetic modificationMerck Sharp & Dohme LLCDec 3, 2015Feb 12, 2031164.9y left
10005256Therapeutic agent with modular analog mechanismMerck Sharp & Dohme LLCJan 22, 2013Feb 21, 2029372.9y left

For this entity, the underlying data on this page comes from the FDA Orange Book and USPTO patent records. The breakdown above is the federal record; the paragraphs below add the per-entity context that makes the headline numbers usable for a real decision rather than just a data lookup.

The methodology behind every numeric value on this page is publicly documented on the the FDA Orange Book and USPTO patent records portal and described in detail on this site’s methodology page. Refresh cadence varies by underlying series; the page surfaces the as-of date for each number so readers can trace any figure back to the source release.

For readers using this page as a decision input, the related-entity pages elsewhere on the site provide the comparison set. The most useful comparison for this entity is typically a peer within U.S. brand-name drugs with similar size, similar exposure, or similar geography — not the national-level summary alone.